NCT02294253View on ClinicalTrials.gov

Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Opioid Dependence
Interventions
DRUG

Buprenorphine/naloxone

30 day oral Buprenorphine/naloxone

Trial Locations (1)

10032

STARS, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02294253 - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone | Biotech Hunter | Biotech Hunter